How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

931 results for

Human Papilloma Virus Vaccine

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Human papilloma virus (HPV) vaccination: Questions and answers Full Text available with Trip Pro

Human papilloma virus (HPV) vaccination: Questions and answers 28894500 2019 01 16 1715-1635 150 5 2017 Sep-Oct Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC Can Pharm J (Ott) Human papilloma virus (HPV) vaccination: Questions and answers. 306-315 10.1177/1715163517712534 Mejilla Allison A Alberta Health Services (Mejilla, Li), University of Alberta Hospital, Edmonton, Alberta. Li Emily E Alberta Health Services (Mejilla, Li), University of Alberta Hospital (...) PMC5582673 Curr Opin Pediatr. 2015 Jun;27(3):405-17 25888153 N Engl J Med. 2015 Feb 19;372(8):711-23 25693011 J Paediatr Child Health. 2014 Dec;50(12):959-65 24909919 Vaccine. 2014 Oct 7;32(44):5845-53 25131743 Pediatrics. 2016 Mar;137(3):e20151968 26908697 CMAJ. 2015 Feb 3;187(2):E74-81 25487660 J Am Pharm Assoc (2003). 2014 Sep-Oct;54(5):558-61 25216887 PLoS One. 2015 Jun 08;10(6):e0129587 26053866 Epidemiol Infect. 2016 Feb;144(3):449-68 26429676 Hum Vaccin Immunother. 2015;11(2):322-9 25692455 Med J

2017 Canadian Pharmacists Journal : CPJ

42. Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finl Full Text available with Trip Pro

Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finl In Finland a vaccination programme against human papillomavirus (HPV) was introduced in November 2013 for girls aged 11-12 years with a catchup for girls 13-15 years. Allegations that HPV vaccine is causing Guillain Barré syndrome (GBS (...) ) and non-specific diagnostic entities, such as chronic fatigue syndrome/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS), continue to surface. We examined population register-based incidence rates of CFS/SEID, GBS and POTS to provide baseline data for future HPV vaccine safety evaluations.First diagnosis of CFS/SEID, GBS and POTS in girls aged 11-15 years were obtained from the National Hospital Discharge Register during 2002-2012. We considered

2017 Papillomavirus Research

43. Will they lead by example? Assessment of vaccination rates and attitudes to human papilloma virus in millennial medical students. Full Text available with Trip Pro

Will they lead by example? Assessment of vaccination rates and attitudes to human papilloma virus in millennial medical students. Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States. It is also well established that HPV viruses are responsible for a variety of cancers. Little is known about the prevailing knowledge and attitudes toward the HPV vaccine in our future healthcare providers, a majority of whom were among the first in the target age group (...) to receive the vaccine; the same vaccine that they will in turn be expected to recommend to their patients. The aims of this pilot study were to examine the HPV vaccination rate among medical students and determine their knowledge about HPV and attitudes toward vaccination.To aid in the development of an HPV educational intervention, a needs assessment survey was administered to discover medical students' knowledge and attitudes toward the HPV vaccine. All medical students at a Midwestern US medical

2017 BMC Public Health

44. Knowledge of Greek adolescents on human papilloma virus (HPV) and vaccination: A national epidemiologic study. Full Text available with Trip Pro

Knowledge of Greek adolescents on human papilloma virus (HPV) and vaccination: A national epidemiologic study. The aim of the present study was to identify the sexual behavior, attitudes, beliefs, and knowledge on sexually transmitted infections (STIs) focused on human papilloma virus (HPV) in the Greek adolescent population. The participants were 4547 adolescents, a representative sample for Greek territory with a mean age of 17 years. After written permission from Greek ministry of education (...) and cervical cancer. This study shows that the low vaccination coverage of the Greek population may be due to lack of information and awareness of the adolescents and their parents. It is our duty to increase our efforts in order to better educate the population and vaccinate the population as early as possible in their reproductive years.

2017 Medicine

45. Nurse led immunisation of school aged children

office. Immunisation data recorded on SystmOne and HPV data tool. References/resources and comments Policies or guidelines National Local Summary of product characteristics for GARDASIL® human papilloma virus vaccine [Types 6, 11, 16, 18] (recombinant, adsorbed) Immunisation against infectious disease (the Green book) Human Papilloma virus (updated November 2008) Check local guidelines References: 1. Department of Health (1998) Review of prescribing, supply and administration of medicines: a report (...) is high or extreme. Rationale – the school nursing service vaccinates approximately 6,000 young people each year against human papilloma virus and diptheria, tetanus and polio. Half the cohort have vaccinations x 4 and the other half x1 = approximately 15,000 injections. As an invasive procedure, using sharps in a non-clinical environment, a risk assessment is necessary. Activity and task Hazards and risks identified People at risk Controls in place Recommended additional controls Post risk rating 1-5

2014 Royal College of Nursing

46. Parental decision-making with regards to vaccination against human papilloma virus in adolescent girls in Hong Kong, China: a prospective cohort study. Full Text available with Trip Pro

Parental decision-making with regards to vaccination against human papilloma virus in adolescent girls in Hong Kong, China: a prospective cohort study.

2016 Lancet

47. Human Papilloma Virus Vaccine

Human Papilloma Virus Vaccine Human Papilloma Virus Vaccine Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Human Papilloma Virus (...) Vaccine Human Papilloma Virus Vaccine Aka: Human Papilloma Virus Vaccine , Quadrivalent Human Papillomavirus Vaccine , HPV Vaccine , Gardasil , Gardasil-9 , Cervarix From Related Chapters II. Epidemiology Under- despite high efficacy and potential to prevent anogenital and oropharyngeal cancer Girls: 57.3% vaccinated (as of 2013 in U.S.) Boys: 34.6% vaccinated (as of 2013 in U.S.) III. Indications ral indications Prevention of Prevention of anal cancer (receptive anal intercourse) Girls and women

2018 FP Notebook

48. Immunisation rates among children in Nuuk Full Text available with Trip Pro

is suggested including continuously monitoring and adjusting of the organisation of the immunisation programme.Bacille Calmette-Guerin immunisation (BCG); Chief Medical Officer (CMO); Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenza B, Pneumococcal (DTP); Electronic medical report (EMR); Hepatitis B (HBV); Human Papilloma Virus (HPV); Measles, Mumps, Rubella (MMR); World Health Organization (WHO). (...) Immunisation rates among children in Nuuk The children immunisation programme in Greenland correlates to the one in Denmark with the addition of the Bacille Calmette-Guerin (BCG)-vaccine and the immunisation against Hepatitis B (HBV). The immunisation rate among children in Greenland has been and is currently unknown and this study aims to estimate the immunisation rates among children in Nuuk from 1 July 2015 until 30 June 2016. We did an observational cross-sectional study based

2018 International Journal Of Circumpolar Health

49. Vaccination in pregnancy (VIP)

(varicella) or human papilloma virus. Published 1 May 2010 Last updated 21 January 2020 — From: Contents The Immunisation department at Public Health England ( ( . . Shingles vaccine administration in pregnancy Shingles vaccine (Zostavax®, Generic Name: Varicella Zoster Virus, Marketed by Sanofi Pasteur MSD) is a live viral vaccine that is not recommended for use in pregnancy. Most women of child-bearing age in the UK are known to be immune to chickenpox. You can reassure a pregnant woman immunised (...) as early as possible. Laboratory diagnosis of past infection is by VZV IgG antibody in serum. If a woman with an uncertain or negative history of chickenpox is found susceptible (VZV IgG negative): contact as soon as you have the result, to discuss the individual case. The immunisation team may recommend varicella zoster immunoglobulin, given within 10 days of the Zostavax immunisation. The virus in both varicella (chickenpox) and shingles vaccines has been weakened: it is safer in humans than

2020 Public Health England

50. "I Think They're All Basically The Same": Parents’ perceptions of human papilloma virus (HPV) vaccine compared to other adolescent vaccines Full Text available with Trip Pro

"I Think They're All Basically The Same": Parents’ perceptions of human papilloma virus (HPV) vaccine compared to other adolescent vaccines Human papillomavirus (HPV) vaccination is recommended for routine administration at ages 11-12 years. However, uptake is lower than for other vaccines that are also routinely recommended for adolescents (MCV4 and Tdap). Understanding parental perceptions of HPV vaccine compared with other vaccines may help to inform strategies to increase uptake.Parents (...) and caregivers (n = 45) of adolescents ages 10-18 years from a low-income, ethnic minority population participated in a qualitative study. Interviews were transcribed verbatim and coded for emergent themes.Many participants perceived the HPV vaccine to be similar to other routine vaccines. Noted similarities included the vaccines' ability to prevent disease, similar methods of administration and belief in health care providers' recommendation. Some parents noted the greater benefit of HPV vaccine

2016 Child: care, health and development

51. Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. (Abstract)

Immunogenicity, Tolerability and Safety in Adolescents of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered with Quadrivalent Human Papilloma Virus Vaccine. This study in healthy adolescents (11 to <18 years) evaluated coadministration of quadrivalent human papillomavirus vaccine (HPV-4), with bivalent rLP2086, a meningococcal serogroup B (MnB) vaccine.Subjects received bivalent rLP2086 + HPV-4, bivalent rLP2086 + saline or saline + HPV-4 at 0, 2 and 6 months. Immune (...) responses to HPV-4 antigens were assessed 1 month after doses 2 and 3. Serum bactericidal assays using human complement (hSBAs) with 4 MnB test strains expressing vaccine-heterologous human complement factor H binding protein (fHBP) variants determined immune responses to bivalent rLP2086. Coprimary objectives were to demonstrate noninferior immune responses with concomitant administration compared with either vaccine alone. Additional endpoints included the proportions of subjects achieving

2016 The Pediatric infectious disease journal Controlled trial quality: uncertain

52. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Full Text available with Trip Pro

The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide.We report on the impact (...) of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine.We performed a non-systematic literature review of studies measuring the burden of HPV-associated disease and infection in Australia before and after introduction of HPV vaccination. We also included key national reports with estimates of HPV-related disease burden.Substantial declines in high-grade cervical disease and genital warts among vaccine-eligible

2018 Euro Surveillance

53. Gardasil 9 - human papillomavirus 9-valent vaccine (recombinant, adsorbed)

protein human papillomavirus type 31 L1 protein human papillomavirus type 33 L1 protein human papillomavirus type 45 L1 protein human papillomavirus type 52 L1 protein human papillomavirus type 58 L1 protein Common Name: human papillomavirus 9-valent vaccine (recombinant, adsorbed) Pharmaco-therapeutic group (ATC Code): J07BM03 Therapeutic indication(s): Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases: ? Premalignant lesions (...) adjuvant. The active components in each MBAP are the highly purified virus-like particles (VLPs) made up of the recombinant major capsid (L1) protein for that HPV type. L1 is the major structural protein of the human papillomavirus viral capsid. 2.2.2. Active Substance General information Native papillomavirus virions have an icosahedral symmetry consisting of 72 pentamers of L1 protein and are nearly spherical with an approximate diameter of 60 nm. For the vaccine, the L1 capsid polypeptide of each

2015 European Medicines Agency - EPARs

54. Vaccination of HIV infected children

– 13-valent pneumococcal conjugate vaccine Hib/MenC - Haemophilus influenzae type b and Neisseria meningitidis capsular group C conjugate vaccine MenC - meningococcal capsular group C conjugate vaccine 4CMenB – multicomponent meningococcal capsular group B protein vaccine LAIV – live attenuate influenza vaccine MMR – measles, mumps, rubella vaccine HPV – human papilloma virus vaccine MenACWY – quadrivalent meningococcal capsular groups A, C, W and Y conjugate vaccine Hep A&B – combined hepatitis (...) A and hepatitis B vaccine BCG - Bacillus Calmette–Guérin vaccine QIV – quadrivalent inactivated influenza vaccine Table 1. Routine childhood immunisations (2018) Age Diseases protected against Vaccine given Trade name Usual site Eight weeks old Diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b (Hib) and hepatitis B Meningococcal group B (MenB) Rotavirus gastroenteritis Pneumococcal (13 serotypes) DTaP/IPV/Hib/HepB MenB Rotavirus PCV Infanrix hexa Bexsero Rotarix Prevenar 13 Thigh Left thigh

2018 The Children's HIV Association

55. Cost-effectiveness analysis of HPV vaccination of boys in Belgium

Publique, France Human papilloma virus Bivalent HPV vaccine, Cervarix® Quadrivalent HPV vaccine, Gardasil® 8 HPV vaccination of boys KCE Report 308 HPV9 Nonavalent HPV vaccine, Gardasil 9® IBM Individual based model ICER Incremental cost-effectiveness ratio MSM Men having sex with men NHS National health system NICE National Institute of Health and Clinical Excellence NIHDI National Institute for Health and Disability Insurance (INAMI/RIZIV) OECD Organisation for Economic Cooperation and Development (...) given four months after the second. These same three doses can also be used in individuals aged nine to thirteen years. 1.2.3 Gardasil 9 The European Commission granted a marketing authorisation valid throughout the European Union for Gardasil 9 on 10 June 2015. Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases: • Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types; • Genital

2019 Belgian Health Care Knowledge Centre

56. Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)

infection and incidence of abnormal cytology after vaccination. The safety of the vaccination (local or systemic reaction and impact on HIV viral control and immunodeficiency level) will be assessed. The cellular immune response will be assessed in a subgroup of patients. Condition or disease Intervention/treatment Phase HPV - Anogenital Human Papilloma Virus Infection HIV Infections Biological: Vaccine Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical (...) a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by Deborah Konopnicki, Centre Hospitalier Universitaire Saint Pierre: vaccine woman Additional relevant MeSH terms: Layout table for MeSH terms Infection Communicable Diseases HIV Infections Virus Diseases Papilloma Papillomavirus Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Sexually Transmitted Diseases, Viral

2017 Clinical Trials

57. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias Full Text available with Trip Pro

Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 . ( accessed May 2018 ). 18. Garland SM , Hernandez-Avila M , Wheeler CM , et al . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases . 19. Muñoz N , Manalastas R , Pitisuttithum P , et al . Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years (...) , Peter C Gøtzsche , Tom Jefferson Statistics from Altmetric.com Key findings The Cochrane human papillomavirus (HPV) vaccine review missed nearly half of the eligible trials. The review was influenced by reporting bias and biased trial designs. Authors of Cochrane reviews should make every effort to identify all trials and the trials’ limitations. In May 2018, the Cochrane Collaboration published its review of the human papillomavirus (HPV) vaccines. The review primarily assessed the vaccines’ effect

2018 Evidence-Based Medicine

58. Current recommendations for vaccines for female infertility patients: a committee opinion

. There is no ACIP recommendation regarding additional vaccination with 9v HPV for those individuals who completed TABLE 1 Summary of the recommended adult immunization schedule outline by the Centers for Disease Control and Prevention (2). Vaccine Age group (y) 19–21 22–26 27–49 50–59 60–64 ‡65 In?uenza a 1 dose annually b Tetanus, diphtheria, pertussis (Td/ Tdap) a Substitute 1-time dose of Tdap for Td booster; then boost with Td every 10 years b Td/Tdap d Varicella e 2 doses b Human papilloma virus (HPV (...) -cell anemia, chronic cardiovascular/pulmonarydisease,diabetes,orimmunocom- promise as may result from human immunode?ciency virus (HIV) infection, systemic illness, or malignancy. Ideally, high-risk women should be immunized before pregnancy. Hepatitis A(HA) HA vaccine is recommended for any women at high risk, including those receiving clotting-factor concentrates, those with chronic liver disease, women working with HA virus or HA-infected laboratory animals, women traveling to coun

2018 Society for Assisted Reproductive Technology

59. HTA of extending the HPV vaccination to boys

, whereby younger populations demonstrated a superior immune response to adults and males demonstrate a superior immune response to females. ? The high efficacy observed in clinical trials is supported by observational studies, whereby the introduction of HPV immunisation programmes has led to significant reductions in HPV-related disease on a population level. ? A large volume of evidence demonstrates the overall safety of HPV vaccines. An overview of reviews, encompassing data from over 70,000 trial (...) of Interest None Health Technology Assessment (HTA) of HPV vaccination of boys Health Information and Quality Authority Page 12 of 450 List of abbreviations used in this report AAHS Amorphous Aluminum Hydroxyphosphate Sulfate AGW Anogenital Wart AIN Anal Intraepithelial Neoplasia AIS Adenocarcinoma In Situ AMSTAR A Measurement Tool To Assess Systematic Reviews BASHH British Association For Sexual Health And HIV BIA Budget Impact Analysis CDC Centers For Disease Control And Prevention CEAC Cost

2018 Health Information and Quality Authority

60. Trumenba - meningococcal group b vaccine (recombinant, adsorbed)

meningitidis ) FMEA Failure Modes and Effects Analysis FP finished product GCP Good Clinical Practice GD Gestation day GMR geometric mean ratio GMT geometric mean titer HAV hepatitis A virus vaccine HCP host cell protein HPV human papilloma virus vaccine hSBA serum bactericidal assay using human complement ICD informed consent document ICH International Conference on Harmonisation IgA Immunoglobulin A IgG Immunoglobulin G IM Intramuscular IMAC Immobilized metal affinity chromatography IMD invasive (...) meningococcal disease IPC in process control IPT-C in process test for control IPT-M in process test for monitor IPV inactivated poliomyelitis virus vaccine ISE integrated summary of efficacy ISS integrated summary of safety IVRA in vitro antigenicity assay iTT intent-to-treat IEX-HPLC Ion-exchange high performance liquid chromatography LAL Limulus amoebocyte lysate assay LCI lower bound confidence interval LLOQ lower limit of quantitation LOD limit of detection LOS lipooligosaccharide LP2086 lipoprotein

2017 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>